What is the 13F Pro Quality Score for AIM?

13F Pro ranks AIM ImmunoTech Inc. (AIM) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View AIM's current score at https://13fpro.ai/company/AIM (free sign-up required for the full ranking).

Which hedge funds own the most AIM stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of AIM include JANE STREET GROUP,, Virtu Financial, MORGAN STANLEY. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/AIM as soon as new 13F filings post.

Where does 13F Pro source AIM data?

All AIM ImmunoTech Inc. fundamentals and ownership data come directly from SEC EDGAR. AIM ImmunoTech Inc. files with the SEC under CIK 946644. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is AIM in?

AIM ImmunoTech Inc. (AIM) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is AIM research updated on 13F Pro?

AIM's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

AIM ImmunoTech Inc.(AIM)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSEsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 946644 AIM stock profile & AI dashboard →

13F Pro Quality Score

9.9/100

Rank #2,912 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why AIM Scores 10/100

exact factor attribution · 2026-09-11

AIM's composite is driven by earnings growth, held back by revenue growth and scale. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Earnings growth

+2.2 pts

95th pct

Institutional flow

-0.2 pts

46th pct

Shareholder dilution

-2.1 pts

7th pct

Earnings quality

-3.9 pts

11th pct

Capital efficiency

-4.8 pts

2th pct

Profitability

-7.3 pts

1th pct

Free cash flow

-7.3 pts

1th pct

Scale

-7.4 pts

1th pct

Revenue growth

-9.3 pts

4th pct

Latest change (2026-08-07): 9 → 4 · ↓ Capital efficiency 30→1

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

AIM Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for AIM ImmunoTech Inc. (AIM), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AIM at 9.9/100 on a 32-signal composite quality model, placing it at rank #2,912 of 2,961 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), AIM ImmunoTech Inc. reports quarterly revenue of $26.0K, net income of $-3.8M. Top institutional holders of AIM by reported 13-F value include JANE STREET GROUP, Virtu Financial, MORGAN STANLEY, based on the most recent SEC filings. AIM trades on the NYSE exchange and files with the SEC under CIK 946644. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AIM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AIM ImmunoTech Inc. directly from SEC EDGAR. AIM ImmunoTech Inc.'s 13F Pro composite quality score has ranged between 4 and 10 since 2026, currently 9.9 — a stable long-term trajectory across 9 quarterly and live scoring snapshots.

✦

Fun facts about AIM ImmunoTech Inc.

Quirks, history, and lore behind AIM — the kind of stuff that makes a stock memorable.

1
The Basics
A micro-cap biopharmaceutical company · listed on NYSE American · headquartered in Florida · focused on immunology and antiviral research.
2
The Numbers
Annual revenues in the low single-digit millions — firmly in clinical-stage territory — with a market cap that has spent years well under $100 million.
3
The History
The company has been pursuing its core drug candidate for decades, originally exploring it as a broad-spectrum antiviral before pivoting toward cancer immunotherapy.
4
The Secret
Its lead compound is a double-stranded RNA molecule — a type of synthetic immune-system activator — studied across chronic fatigue syndrome, HIV, and solid tumors.
5
The Lore
The drug has been in clinical development so long it has become something of a cult obsession among patient advocates, particularly those with myalgic encephalomyelitis / chronic fatigue syndrome.
6
The Giveaway
Its flagship compound is called Ampligen (rintatolimod) — one of the few drugs ever to receive an FDA complete response letter for chronic fatigue syndrome, keeping hope alive for a very devoted patient community.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$26.0K

Net Income

Q2 2026

$-3.8M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-48.2% YoY

$88.0KFY 2025

FY22 $141.0KFY23 $202.0KFY24 $170.0KFY25 $88.0K

Net Income

+19.4% YoY

$-14.0MFY 2025

FY22 $-19.4MFY23 $-29.0MFY24 $-17.3MFY25 $-14.0M

Operating Income

+41.0% YoY

$-11.7MFY 2025

FY22 $-19.9MFY23 $-31.9MFY24 $-19.8MFY25 $-11.7M

EPS (Diluted)

+72.1% YoY

$-8.61FY 2025

FY22 $-0.40FY23 $-0.60FY24 $-30.89FY25 $-8.61

Total Assets

-32.8% YoY

$5.8MFY 2025

FY22 $40.5MFY23 $19.4MFY24 $8.6MFY25 $5.8M

Total Debt

+56.9% YoY

$8.0MFY 2025

FY22 —FY23 —FY24 $5.1MFY25 $8.0M

Op. Cash Flow

+26.4% YoY

$-11.0MFY 2025

FY22 $-16.1MFY23 $-21.3MFY24 $-14.9MFY25 $-11.0M

Free Cash Flow

—FY 2025

FY22 $-16.2MFY23 —FY24 $-14.9MFY25 —

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$88.0K -48.2%	$170.0K -15.8%	$202.0K +43.3%	$141.0K +4.4%	$135.0K -17.2%	$163.0K
Net Income	$-14.0M +19.4%	$-17.3M +40.2%	$-29.0M -48.9%	$-19.4M -1.7%	$-19.1M -32.8%	$-14.4M
Operating Income	$-11.7M +41.0%	$-19.8M +38.0%	$-31.9M -60.2%	$-19.9M -5.8%	$-18.8M -24.3%	$-15.2M
EPS (Diluted)	$-8.61 +72.1%	$-30.89 -5053.3%	$-0.60 -50.0%	$-0.40	—	—
Total Assets	$5.8M -32.8%	$8.6M -55.6%	$19.4M -52.1%	$40.5M -29.8%	$57.7M -10.7%	$64.6M
Total Debt	$8.0M +56.9%	$5.1M	—	—	—	$2.3M
Operating Cash Flow	$-11.0M +26.4%	$-14.9M +30.0%	$-21.3M -32.0%	$-16.1M -15.3%	$-14.0M -34.7%	$-10.4M
Free Cash Flow	—	$-14.9M	—	$-16.2M -15.6%	$-14.0M -34.8%	$-10.4M

Get alerted when AIM's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for AIM ImmunoTech Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of AIM

JANE STREET GROUP, LLC
$229.4K807,885 sh
Virtu Financial LLC
$35.0K124,269 sh
MORGAN STANLEY
$14.4K50,864 sh
GEODE CAPITAL MANAGEMENT, LLC
$13.1K46,003 sh
GOLDMAN SACHS GROUP INC
$9.2K32,444 sh
UBS Group AG
$8.2K28,931 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$6.2K21,859 sh
VANGUARD FIDUCIARY TRUST CO
$5.0K17,519 sh
Ground Swell Capital, LLC
$3.5K12,222 sh
Tower Research Capital LLC (TRC)
$1.3K4,668 sh

Fund	Value	Shares
JANE STREET GROUP, LLC	$229.4K	807,885
Virtu Financial LLC	$35.0K	124,269
MORGAN STANLEY	$14.4K	50,864
GEODE CAPITAL MANAGEMENT, LLC	$13.1K	46,003
GOLDMAN SACHS GROUP INC	$9.2K	32,444
UBS Group AG	$8.2K	28,931
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$6.2K	21,859
VANGUARD FIDUCIARY TRUST CO	$5.0K	17,519
Ground Swell Capital, LLC	$3.5K	12,222
Tower Research Capital LLC (TRC)	$1.3K	4,668

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put AIM on your watchlist

Track score changes the day AIM ImmunoTech Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is AIM a good stock to buy?

13F Pro's AI-powered analysis of AIM ImmunoTech Inc. (AIM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AIM are available on the AIM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. AIM is classified as a small company.

Which hedge funds own AIM?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AIM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of AIM ImmunoTech Inc.'s investment landscape.